Humabiologics products are now available to researchers in Japan for use in regenerative medicine translational research, cell therapy, bioprinting, tissue & disease modeling, and drug screening applications.
Press Release November 1, 2021
PHOENIX, Arizona – Humabiologics, an industry leader in providing human-derived biomaterials for regenerative medicine, and Funakoshi Co., Ltd, a leader in manufacturing and distributing life sciences research supplies for 50 years in Japan, has entered into a non-exclusive agreement to respond to the growing demand and serve a broader life sciences customer base of industry partners and academic institutions in the Japanese market.
Humabiologics develops and commercializes high quality and affordable human-derived biomaterials for translational regenerative medicine applications such as cell therapy, bioprinting, tissue & disease modeling, or drug screening.
“We are delighted to partner with Funakoshi to make our human products more accessible to researchers in Japan. Funakoshi is a strategic partner with long history and reputation of manufacturing and distributing of life sciences reagents and equipment for life sciences research”, said Dr. Mohammad Albanna, CEO & Founder of Humabiologics. “We look forward to a long-lasting relationship with Funakoshi and to serve their customers with our products to accelerate the development of life saving human therapies”.
Funakoshi has been offering several useful tools with leading edge technologies for Japanese researchers from all over the world to support and develop their research.
Humabiologics is a regenerative medicine company founded by scientists and tissue industry experts to address the gap between the gift of donated human tissues and researchers. Learn more at https://humabiologics.com
Dr. Mohammad Albanna, Founder & CEO
(312) 479 5199